SCHEMBL9980919

SCHEMBL9980919

COc1cc(-n2cccn2)ccc1-n1ccc(=O)c(-c2ccnn2-c2cccc(Cl)c2)n1

nearest known ligand 0.57

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 11/20 0.57
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 3/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CRHR1 P34998 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9980862 0.91 PDE10A (0.55) PDE10AALDH1A1
SCHEMBL9981982 0.90 PDE10A (0.45) PDE10AKDM4EALDH1A1HPGDNPSR1
SCHEMBL10039758 0.89 PDE10A (0.55) PDE10AKDM4EALDH1A1HPGD
SCHEMBL12045863 0.88 PDE10A (0.60) PDE10AKDM4EALDH1A1HPGDCRHR1
SCHEMBL12060224 0.88 PDE10A (0.51) PDE10AKDM4EALDH1A1HPGD
SCHEMBL12060213 0.87 PDE10A (0.66) PDE10AKDM4EALDH1A1HPGDNPSR1
SCHEMBL9981118 0.87 PDE10A (0.53) PDE10AKDM4EALDH1A1HPGD
SCHEMBL9981254 0.87 PDE10A (0.53) PDE10AKDM4EALDH1A1HPGDNPSR1
SCHEMBL9980868 0.86 PDE10A (0.60) PDE10AKDM4EALDH1A1HPGD
SCHEMBL9980983 0.85 PDE10A (0.41) PDE10AKDM4EALDH1A1HPGDCRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797963-B1 HYPERBRANCHED OLEFIN OIL-BASED DIELECTRIC FLUID DOW GLOBAL TECHNOLOGIES LLC (US) 2019-07-03 EP claimed
US-9601231-B2 Hyperbranched olefin oil-based dielectric fluid DOW GLOBAL TECHNOLOGIES LLC (US) 2017-03-21 US claimed
US-9522855-B2 Process for producing low molecular weight ethylene- and alpha-olefin-based materials DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-20 US claimed
EP-2797962-B1 PROCESS FOR PRODUCING LOW MOLECULAR WEIGHT ETHYLENE- AND ALPHA-OLEFIN-BASED MATERIALS DOW GLOBAL TECHNOLOGIES LLC (US) 2015-11-18 EP claimed
US-20140357918-A1 PROCESS FOR PRODUCING LOW MOLECULAR WEIGHT ETHYLENE- AND ALPHA-OLEFIN-BASED MATERIALS DOW GLOBAL TECHNOLOGIES LLC (US) 2014-12-04 US claimed
US-20140330056-A1 HYPERBRANCHED OLEFIN OIL-BASED DIELECTRIC FLUID DOW GLOBAL TECHNOLOGIES LLC (US) 2014-11-06 US claimed
US-11155738-B2 Branched triglyceride-based fluids useful for dielectric and/or heat transfer applications DOW GLOBAL TECHNOLOGIES LLC (US) 2021-10-26 US disclosed
US-20200115606-A1 Branched Triglyceride-Based Fluids Useful for Dielectric and/or Heat Transfer Applications DOW GLOBAL TECHNOLOGIES LLC 2020-04-16 US disclosed
EP-3209744-B1 ELECTRICAL DEVICES COMPRISING DIELECTRIC FLUIDS BASED ON BRANCHED TRIGLYCERIDE DOW GLOBAL TECHNOLOGIES LLC (US) 2019-07-31 EP disclosed
EP-2797963-B1 HYPERBRANCHED OLEFIN OIL-BASED DIELECTRIC FLUID DOW GLOBAL TECHNOLOGIES LLC (US) 2019-07-03 EP disclosed
US-20170349800-A1 Branched Triglyceride-Based Fluids Useful for Dielectric and/or Heat Transfer Applications DOW GLOBAL TECHNOLOGIES LLC 2017-12-07 US disclosed
US-9601231-B2 Hyperbranched olefin oil-based dielectric fluid DOW GLOBAL TECHNOLOGIES LLC (US) 2017-03-21 US disclosed
US-9601231-B2 Hyperbranched olefin oil-based dielectric fluid DOW GLOBAL TECHNOLOGIES LLC (US) 2017-03-21 US disclosed
US-8563575-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-22 US disclosed
US-8563575-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-22 US disclosed
WO-2013101376-A1 HYPERBRANCHED OLEFIN OIL-BASED DIELECTRIC FLUID DOW GLOBAL TECHNOLOGIES LLC (US) 2013-07-04 WO disclosed
US-20130172328-A1 FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS CROSSWING INC. (CA) 2013-07-04 US disclosed
US-20130172328-A1 FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS CROSSWING INC. (CA) 2013-07-04 US disclosed
US-20110319394-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-29 US disclosed
US-20110319394-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357918-A1 PROCESS FOR PRODUCING LOW MOLECULAR WEIGHT ETHYLENE- AND ALPHA-OLEFIN-BASED MATERIALS EEF1D, EPN1, ELOC PDE10A 4787/4885KDM4E 2288/4885ALDH1A1 4014/4885
US-20130172328-A1 FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS PDE3A, PDE5A, PDE2A PDE10A 13/4885KDM4E 1979/4885ALDH1A1 166/4885
US-20110319394-A1 FUSED HETEROCYCLIC COMPOUNDS PDE5A, PDE2A, PDE3A PDE10A 12/4885KDM4E 896/4885ALDH1A1 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.